| Date | Title | |
| 11/11/08 | OSI Pharmaceuticals to Present at the Lazard Annual Healthcare Conference on Tuesday, November 18, 2008 |  |
| 11/07/08 | Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer | |
| 10/22/08 | OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results | |
| 10/10/08 | OSI Pharmaceuticals to Announce Third Quarter Financial Results on October 22, 2008 | |
| 10/06/08 | Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer | |
| 10/01/08 | OSI Pharmaceuticals Announces Conversion Period for Convertible Notes | |
| 09/15/08 | OSI Pharmaceuticals to Present at the UBS Global Life Sciences Conference on Monday, September 22, 2008 | |
| 09/03/08 | OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821 | |
| 07/23/08 | OSI Pharmaceuticals Announces Second Quarter 2008 Financial Results | |
| 07/15/08 | OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma | |
| 07/09/08 | OSI Pharmaceuticals to Announce Second Quarter Financial Results on July 23, 2008 | |
| 07/03/08 | OSI Pharmaceuticals Announces Conversion Period for Convertible Notes | |
| 06/19/08 | OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602 | |
| 06/10/08 | OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical Compounds, PSN821 and PSN602, at Annual Meeting of the American Diabetes Association | |
| 06/04/08 | OSI Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference on Thursday, June 12, 2008 | |
| 05/27/08 | OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2008 American Society of Clinical Oncology Meeting | |
| 05/14/08 | OSI Pharmaceuticals to Present at the Citi Global Healthcare Conference on Thursday, May 22, 2008 | |
| 05/06/08 | OSI Pharmaceuticals Announces First Quarter 2008 Financial Results | |
| 05/06/08 | OSI Pharmaceuticals to Present at the Bank of America Healthcare Conference on Tuesday, May 13, 2008 | |
| 04/25/08 | OSI Pharmaceuticals to Announce First Quarter Financial Results on May 6, 2008 | |
| 04/23/08 | OSI Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1, 2008 | |
| 04/16/08 | OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research | |
| 04/04/08 | OSI Pharmaceuticals Announces Conversion Period for Convertible Notes | |
| 03/18/08 | OSI Pharmaceuticals Announces That the Prior Revocation of Its European DP-IV Patent Has Been Upheld | |
| 03/14/08 | OSI Pharmaceuticals Announces Preliminary Agreement to Settle Class Action Lawsuit | |
| 03/12/08 | OSI Pharmaceuticals to Present at the Lehman Brothers Global Healthcare Conference on Wednesday, March 19, 2008 | |
| 02/29/08 | OSI Pharmaceuticals Reports Intention to File Shelf Registration Statement in Connection with Previously Issued Convertible Notes | |
| 02/27/08 | OSI Pharmaceuticals Seeks to Strengthen Tarceva Patent by Filing Re-Issue Application with the U.S. Patent and Trademark Office | |
| 02/21/08 | OSI Pharmaceuticals Announces Year End 2007 Financial Results | |
| 02/05/08 | OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2007 Financial Results on February 21, 2008 | |
| 01/29/08 | OSI Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008 | |
| 01/23/08 | OSI Pharmaceuticals to Present at the Wachovia 2008 Healthcare Conference on Wednesday, January 30, 2008 | |
| 01/10/08 | OSI Pharmaceuticals to Present at the Stanford Group Company 13th Annual Healthcare Conference on Thursday, January 17, 2008 | |
| 01/08/08 | OSI Pharmaceuticals Announces Conversion Period for Convertible Notes | |
| 01/04/08 | OSI Pharmaceuticals, Inc. Prices $175 Million 3% Convertible Senior Subordinated Note Offering | |
| 01/02/08 | OSI Announces Intention to Offer $150 Million of Convertible Senior Subordinated Notes | |
